n/a
Abstract Title:

Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort.

Abstract Source:

Fertil Steril. 2013 Dec ;100(6):1660-6. Epub 2013 Sep 5. PMID: 24011610

Abstract Author(s):

Britton Trabert, Emmet J Lamb, Bert Scoccia, Kamran S Moghissi, Carolyn L Westhoff, Shelley Niwa, Louise A Brinton

Article Affiliation:

Britton Trabert

Abstract:

OBJECTIVE: To examine the relationship of ovulation-inducing drugs and ovarian cancer.

DESIGN: Retrospective cohort study, with additional follow-up since initial report.

SETTING: Five large reproductive endocrinology practices.

PATIENT(S): In a retrospective cohort of 9,825 women evaluated for infertility at five clinical sites in the United States between 1965 and 1988 with follow-up through 2010, we examined the relationship of ovulation-inducing drugs and ovarian cancer (n = 85).

INTERVENTION(S): None.

MAIN OUTCOME MEASURE(S): Hazard rate ratios (RR) and 95% confidence intervals (CI) for ovarian cancer.

RESULT(S): Among women evaluated for infertility, there was no association of ovarian cancer risk with ever use of clomiphene citrate (CC) (adjusted RR 1.34, 95% CI 0.86-2.07) or gonadotropins (RR 1.00, 95% CI 0.48-2.08) and no evidence that any of several more detailed subgroups of usage were related to an increased risk with one exception: women who used CC and remained nulligravid did demonstrate much higher risks than those who successfully conceived compared with nonusers (respectively, RR 3.63, 95% CI 1.36-9.72 vs. RR 0.88, 95% CI 0.47-1.63).

CONCLUSION(S): Our overall results were reassuring and consistent with other studies. A reason for an association between CC use and ovarian cancer among persistently nulligravid women remains to be determined. Given the large and increasing number of women treated with ovulation-inducing drugs, the increased risk of ovarian cancer among the subset of women who remained nulligravid should be further monitored.

Study Type : Human Study
Additional Links
Adverse Pharmacological Actions : Carcinogenic : CK(1000) : AC(144)

Print Options


Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2020 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.